Pyrazinamide and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Pyrazinamide (pyrazinamide), especially for people who are male, 30-39 old, have been taking the drug for 1 - 6 months also take Kanamycin, and have Pulmonary tuberculosis.

The phase IV clinical study analyzes which people have Hearing loss when taking Pyrazinamide. It is created by eHealthMe based on reports of 10,019 people who have side effects when taking Pyrazinamide from the FDA, and is updated regularly.

What is Pyrazinamide?

Pyrazinamide has active ingredients of pyrazinamide. It is often used in tuberculosis. eHealthMe is studying from 10,062 Pyrazinamide users. Check the latest studies of Pyrazinamide.

What is Hearing loss?

Hearing loss is found to be associated with 1,355 drugs and 2,378 conditions by eHealthMe. Check the latest studies of Hearing loss.

On Jul, 16, 2026

10,019 people reported to have side effects when taking Pyrazinamide.
Among them, 49 people (0.49%) have Hearing loss.

Among these 49 people:

How long have people been on Pyrazinamide when they have Hearing loss? *

What is the gender of people who have Hearing loss when taking Pyrazinamide? *

female: 23.68 %
male: 76.32 %

What is the age of people who have Hearing loss when taking Pyrazinamide? *

What are other drugs people take besides Pyrazinamide? *

What are other side effects people have besides Hearing loss? *

Dizziness: 11 people, 22.45%
Nausea And Vomiting: 11 people, 22.45%
Tinnitus (a ringing in the ears): 10 people, 20.41%
Joint Pain: 9 people, 18.37%
Nausea (feeling of having an urge to vomit): 9 people, 18.37%
Drug Resistance (reduction in effectiveness of a drug): 9 people, 18.37%
Neuropathy Peripheral (surface nerve damage): 9 people, 18.37%
Visual Impairment: 5 people, 10.20%
Visual Acuity Reduced (reduced clearness of vision): 5 people, 10.20%
Ototoxicity (damage to the ear): 5 people, 10.20%

What are the existing conditions these people have? *

Pulmonary Tuberculosis (lungs tuberculosis): 5 people, 10.20%
Meningitis Tuberculous (a bacterial infection of the membranes covering the brain and spinal cord (meninges)): 4 people, 8.16%
Disseminated Tuberculosis: 4 people, 8.16%
Tuberculosis Of Genitourinary System (a bacterial infection of genitourinary tract by mycobacterium tuberculosis): 2 people, 4.08%
Tuberculosis Bladder (a bacterial infection of bladder by mycobacterium tuberculosis): 2 people, 4.08%
Retroviral Infection (viral infection): 2 people, 4.08%
Pachymeningitis (inflammation of the dura mater or outer membrane of the brain): 2 people, 4.08%
Osteoporosis (bones weak and more likely to break): 2 people, 4.08%
Bone Tuberculosis: 2 people, 4.08%
Pneumonia: 1 person, 2.04%

* Approximation only. Some reports may have incomplete information.

Do you take Pyrazinamide and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pyrazinamide:

Pyrazinamide (10,062 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Pyrazinamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,355 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,378 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pyrazinamide (the active ingredients of Pyrazinamide) and Pyrazinamide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.